About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers

January 6, 2021
Kevin123987

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment

 

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

 

The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:

  • Type of molecule
  • Small Molecule
  • Biologic

 

  • Target disease indication
  • Breast Cancer
  • Colorectal Cancer
  • Fallopian Tube Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Others

 

  • Type of synlet target
  • APE1 / Ref-1
  • Chk1
  • GLS1
  • PARP
  • Pol θ
  • PP2A
  • Wee1

 

  • Route of administration
  • Oral
  • Intravenous

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 

The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:

  • AbbVie
  • AstraZeneca
  • AtlasMedx
  • BeiGene
  • Chordia Therapeutics
  • Clovis Oncology
  • GlaxoSmithKline
  • IDEAYA Biosciences
  • Mission Therapeutics
  • Pfizer
  • Repare Therapeutics
  • Sierra Oncology
  • SyntheX Labs

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction to DNA Damage and Repair Systems
  3. Introduction to Synthetic Lethality
  4. Market Overview
  5. Company Profiles
  6. Emerging Trends on Social Media
  7. Publication Analysis
  8. Abstract Analysis
  9. Academic Grants Analysis
  10. Funding and Investment Analysis
  11. Target Benchmark Analysis

 

  1. Role of Companion Diagnostics in Synthetic Lethality

 

  1. Market Forecast
  2. Concluding Remarks
  3. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Article Categories:
HEALTH

Leave a Comment